Navigation Links
Verenium to Present at Upcoming Conferences
Date:5/11/2011

SAN DIEGO, May 11, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced James Levine, President and Chief Executive Officer, will present at two upcoming conferences.

Mr. Levine will present at the upcoming Barclays Capital Clean Solutions Conference as part of the "Biofuels" panel discussion scheduled from 1:30 – 3:00 p.m. ET on Thursday, May 19, 2011 in New York City.  Webcast information is unavailable at this time and will be posted to the "Investors" section of the Verenium website when available.

Mr. Levine will also present at the upcoming at the Stifel Nicolaus 2011 Cleantech Conference on Tuesday, May 24, 2011.  The presentation is expected to begin at 10:15 a.m. ET and will take place at the Omni Berkshire Place in New York City.  The live webcast may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com.  A webcast replay will be accessible for 30 days following the conference.  

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to Verenium's lines of business, operations, capabilities, commercialization activities, corporate partnersh
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
2. Verenium Corporation to Present at the William Blair & Company 2008 Small-Cap Growth Stock Conference
3. Verenium Corporation to Announce Third Quarter 2008 Financial Results
4. Verenium Corporation to Speak at the Credit Suisse Alternative Energy Conference
5. Verenium Regains Compliance With Nasdaq Continued Listing Requirement
6. Verenium Announces First Commercial Cellulosic Ethanol Project
7. Verenium Announces Organizational Changes
8. Verenium Completes Amendment to 8% Senior Convertible Notes
9. BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol
10. Verenium Announces Reverse Stock Split to Take Effect September 9
11. Verenium 1:12 Reverse Stock Split Takes Effect
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... LANSING, Mich. , March 27, 2015  Neogen ... Properties, LLC, has adopted a prearranged trading plan in ... James Herbert , Chairman and CEO of Neogen Corporation, ... shares of Neogen Corporation common stock. Herbert ... the disclosure was appropriate. The filing is only for ...
(Date:3/27/2015)... , March 27, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... and 12 months ended December 31, 2014.  ... million), or ($0.05) per share, for the three months ...
(Date:3/26/2015)... The Market Element LLC, a leading inbound ... Designing Gig LLC to provide website design, development, and ... this alliance with Designing Gig represents a pivotal moment ... comprehensive, end-to-end, digital solution for our clients, which now ... Miller, president of The Market Element. “For small and ...
(Date:3/26/2015)... 26, 2015 ReliantHeart, Inc., an innovative ... a supplier of precision transit-time flow measurement solutions, are ... improve the efficiency of the HeartAssist5® Left ... to experience greater mobility and peace of mind. ... flow board, will draw 1/6th of the power required ...
Breaking Biology Technology:Neogen CEO adopts 10b5-1 Trading Plan 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6The Market Element LLC and Designing Gig LLC Form Strategic Alliance 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... 4 /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin ... company in the People,s Republic,of China, today announced ... its common stock which will begin trading under ... Genesis, common stock will no longer trade,under the ...
... Shandong, China, Sept. 4 /Xinhua-PRNewswire-FirstCall/ --,China Biologic ... Biologic",or the "Company"), one of the leading ... China (the "PRC"), today announced that on,August ... Drug Administration (the "SFDA"),granted China Biologic,s production ...
... EDMONTON, Sept. 4 /PRNewswire-FirstCall/ - BioMS Medical Corp. ... multiple sclerosis (MS), today,announced that the Food and ... fast track designation for the Company,s lead drug, ... (SPMS). Dirucotide,(MBP8298) is currently being evaluated in a ...
Cached Biology Technology:Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 2Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol 3China Biologic's Production Facility Renews GMP Certification 2China Biologic's Production Facility Renews GMP Certification 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 2BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 3BioMS Medical's lead drug, dirucotide (MBP8298) for the treatment of multiple sclerosis, receives fast track designation from FDA 4
(Date:3/24/2015)... NexID Biometrics LLC, whose spoof-mitigation technology boosts protection ... beginning of shipments of version 2.0 of its industry ... in Potsdam, N.Y. , is making ... here today at the Walter E. Washington Convention Center. ... boosts the accuracy rate range to 96.5 to 99.5 ...
(Date:3/23/2015)... 23, 2015   HOYOS Labs , a leading ... announced that the Company will demonstrate multiple biometrics-based technologies ... consumers at Connect:ID on March 23 through 25, 2015, ... will highlight the IEEE Biometric Open Protocol Standard; free ... enterprise access control system. BOPS was invented by HOYOS ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
Breaking Biology News(10 mins):NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3
... and Shenzhen, China, September 30, 2013 - China,s genomics ... the initiation of a joint project to unravel the ... of over $900k, the project will be one of ... involve experts from the IPATIMUP, a leading cancer research ...
... Pace recognizes that we are at a critical time in ... decrease in new HIV infections worldwide and increasing numbers of ... and vaccine research and new evidence on Treatment as Prevention, ... Sharon Lewin, Local Co-Chair of AIDS 2014, Head of the ...
... the human body, particularly neuroproteins that maintain proper brain ... and Parkinson,s are known as "tangle diseases" because they ... in the brain. A team of Australian and ... BMAA can be inserted into neuroproteins, causing them to ...
Cached Biology News:New mechanism for protein misfolding may link to ALS 2
Ps-Aeruginosa (IgA) -Ab EIA Sample Size: 100 l...
Request Info...
Candida (IgG) -Ab EIA Sample Size: 5 l...
... (Competitive) EIA Principle: The Oxidized LDL ... 4E6. Oxidized LDL in the sample competes with ... the microtiter well for the binding of the ... Sample Size: 25 l The Oxidized ...
Biology Products: